Buntanetap市場：市場規模、予測、新たな洞察- 2032年

Buntanetap（旧名：ANVS401またはポジフェン）は、合成経口神経毒性凝集タンパク質（TINAPs）阻害剤であり、神経毒性タンパク質のレベルを低下させ、結果として脳内の毒性を軽減します。Buntanetapは経口投与可能な低分子化合物で、そのユニークな作用機序により、神経変性の主原因の一つである複数の神経毒性タンパク質-APP/AB（APP）、タウ/ホスホ-タウ（タウ）、a-シヌクレイン（aSYN）-を一度に阻害し、運動機能を改善することができます。

米国FDAは、早期および進行パーキンソン病に対するBuntanetapの第III相試験への開発継続を承認しました。現在、Buntanetapは早期パーキンソン病の第III相試験で研究されており、同社は2023年末までに試験を完了する予定です。同社はまた、アルツハイマー病やその他の神経変性疾患に対してもBuntanetapを開発しています。

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、Buntanetapの優位性に影響を与える可能性のある機会を模索しています。パーキンソン病に対する他の新興製品は、Buntanetapとの厳しい市場競争になると予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のBuntanetap市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるBuntanetapの概要

• 製品の詳細
• 臨床開発
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 Buntanetap市場評価

• パーキンソン病におけるBuntanetapの市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療におけるBuntanetapの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Buntanetap, Clinical Trial Description, 2023
• Table 2: Buntanetap, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: Buntanetap Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Buntanetap Market Size in the US, in USD million (2019-2032)
• Table 7: Buntanetap Market Size in Germany, in USD million (2019-2032)
• Table 8: Buntanetap Market Size in France, in USD million (2019-2032)
• Table 9: Buntanetap Market Size in Italy, in USD million (2019-2032)
• Table 10: Buntanetap Market Size in Spain, in USD million (2019-2032)
• Table 11: Buntanetap Market Size in the UK, in USD million (2019-2032)
• Table 12: Buntanetap Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Buntanetap Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Buntanetap Market Size in the United States, USD million (2019-2032)
• Figure 3: Buntanetap Market Size in Germany, USD million (2019-2032)
• Figure 4: Buntanetap Market Size in France, USD million (2019-2032)
• Figure 5: Buntanetap Market Size in Italy, USD million (2019-2032)
• Figure 6: Buntanetap Market Size in Spain, USD million (2019-2032)
• Figure 7: Buntanetap Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Buntanetap Market Size in Japan, USD million (2019-2032)

"Buntanetap Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about buntanetap for Parkinson's disease in the seven major markets. A detailed picture of the buntanetap for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the buntanetap for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the buntanetap market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

Buntanetap (previously known as ANVS401 or posiphen) is a synthetically produced oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which lowers the level of neurotoxic proteins and consequently less toxicity in the brain. Buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins-APP/AB (APP), tau/phospho-tau (tau), and a-Synuclein (aSYN)-that is one of the main causes of neurodegeneration at once and improve motor function.

The US FDA has green-lighted the continued development of Buntanetap into phase III for early and advanced Parkinson's disease. Presently buntanetap is being studied in a Phase III early Parkinson's disease study and the company expects to complete the trial by the end of 2023. The company is also developing buntanetap for Alzheimer's disease and other neurodegenerative conditions.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the buntanetap description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on buntanetap regulatory milestones and other development activities have been provided in this report.
• The report also highlights the buntanetap research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around buntanetap.
• The report contains forecasted sales of buntanetap for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for buntanetap in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Buntanetap Analytical Perspective by DelveInsight

• In-depth Buntanetap Market Assessment

This report provides a detailed market assessment of buntanetap for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Buntanetap Clinical Assessment

The report provides the clinical trials information of buntanetap for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence buntanetap dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to buntanetap and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of buntanetap in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of buntanetap from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the buntanetap in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of buntanetap?
• What is the clinical trial status of the study related to buntanetap in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the buntanetap development?
• What are the key designations that have been granted to buntanetap for Parkinson's disease?
• What is the forecasted market scenario of buntanetap for Parkinson's disease?
• What are the forecasted sales of buntanetap in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to buntanetap for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. Buntanetap Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Buntanetap Market Assessment

• 5.1. Market Outlook of Buntanetap in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Buntanetap in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Buntanetap in the United States for Parkinson's disease
  • 5.3.2. Market Size of Buntanetap in Germany for Parkinson's disease
  • 5.3.3. Market Size of Buntanetap in France for Parkinson's disease
  • 5.3.4. Market Size of Buntanetap in Italy for Parkinson's disease
  • 5.3.5. Market Size of Buntanetap in Spain for Parkinson's disease
  • 5.3.6. Market Size of Buntanetap in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of Buntanetap in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options